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Abstract
Glioblastoma multiforme (GBM) are the most malignant among brain tumors. They are frequently refractory to
chemotherapy and radiotherapy with mean patient survival of approximately 6 months, despite surgical interven-
tion. The highly glycolytic nature of glioblastomas describes their propensity to metabolize glucose to lactic acid at
an elevated rate. To survive, GBMs efflux lactic acid to the tumor microenvironment through transmembrane trans-
porters denoted monocarboxylate transporters (MCTs). We hypothesized that inhibition of MCT function would
impair the glycolytic metabolism and affect both glioma invasiveness and survival. We examined the effect on
invasiveness with α-cyano-4-hydroxy-cinnamic acid (ACCA, 4CIN, CHCA), a small-molecule inhibitor of lactate trans-
port, through Matrigel-based and organotypic (brain) slice culture invasive assays using U87-MG and U251-MG gli-
oma cells. We then conducted studies in immunodeficient rats by stereotaxic intracranial implantation of the glioma
cells followed by programmed orthotopic application of ACCA through osmotic pumps. Effect on the implanted tu-
mor was monitored by small-animal magnetic resonance imaging. Our assays indicated that glioma invasion was
markedly impaired when lactate efflux was inhibited. Convection-enhanced delivery of inhibitor to the tumor bed
caused tumor necrosis, with 50% of the animals surviving beyond the experimental end points (3 months after in-
hibitor exhaustion). Most importantly, control animals did not display any adverse neurologic effects during ortho-
topic administration of ACCA to brain through programmed delivery. These results indicate the clinical potential of
targeting lactate efflux in glioma through delivery of small-molecule inhibitors of MCTs either to the tumor bed or to
the postsurgical resection cavity.
Neoplasia (2011) 13, 620–632
Address all correspondence to: Saroj P. Mathupala, PhD, Department of Neurological Surgery & Karmanos Cancer Institute, Wayne State University School of Medicine, 607
HWCRC, 4100 John R., Detroit, MI 48201. E-mail: smathupala@med.wayne.edu
1Research support was provided by grants from the American Cancer Society IRG-85-003-14 (S.P.M.); LEARN Foundation, Mich (S.P.M.); the National Institutes of Health
(CA116257 to S.P.M.); Marvin E. Klein, MD, Charitable Trust (S.P.M.); the Fund for Medical Research and Education, Wayne State University School of Medicine (C.C.);
the Joe Young Fund for Research in Psychiatry (M.P.G.); and the Anesthesiology Fund for Medical Research (M.P.G. and F.G.). None of the authors of this article received any
financial support in conjunction with the generation of this submission. None of the authors have a financial conflict of interest.
Received 8 January 2011; Revised 6 May 2011; Accepted 12 May 2011
Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00
DOI 10.1593/neo.11134
www.neoplasia.com
Volume 13 Number 7 July 2011 pp. 620–632 620
Introduction
The most common type of malignant tumor that occurs in brain (pri-
mary brain tumors) is referred to as glioblastoma. Unfortunately, it is
also the most lethal. Current data and projections indicate that, in the
United States, an estimated 22,000 new cases of brain tumor will be
diagnosed in 2010, whereas 13,000 deaths will occur due to the same
(www.abta.org), a dismal statistic at best. Brain tumors are the second
leading cause of cancer-related deaths in males up to age 39 and in
females and children younger than 20 years. The incidence of primary
brain tumors increases with age, peaking at ages 75 to 84 years.
The standard therapy for patients diagnosed with malignant brain
tumors is surgical debulking (removal) of the tumor followed by
radiotherapy and chemotherapy. Even with such multimodal interven-
tions, the prognosis for patients remains dismal, with a mean survival of
6 to 12 months from the time of diagnosis. These discouraging facts
clearly indicate a need for alternative approaches to target these tumors.
One such avenue is to attack the deviant metabolic pathways that
are present in glioblastoma, a feature common to most highly malig-
nant tumors. Primarily, such tumors have the propensity to consume
copious amounts of glucose at a rapid rate and convert most of it
to lactic acid, even in the presence of ample oxygen [1–5]. Termed
“aerobic glycolysis,” this metabolic phenotype markedly contrasts
with that observed in normal tissues, where glycolysis (conversion
of glucose to lactic acid) primarily occurs under hypoxic conditions.
To maintain the enhanced glycolytic flux, glioblastomas need to
rapidly efflux lactic acid to the tumor microenvironment, which is
facilitated by a set of plasma membrane transporters denoted mono-
carboxylate transporters (MCTs) [6]. Although 14 isoforms of MCTs
have been identified during in silico analysis of the human genome,
only four (MCTs 1-4) are known to play a role in lactic acid trans-
port in mammalian tissues, including tumors [7].
Previous studies by us [8] and others [9–12] have demonstrated
differential expression of MCT isoforms in brain tumors in contrast
to normal brain tissue. In vitro studies that used RNA interference to
target brain tumor–expressed MCT isoforms to selectively interfere
with lactate efflux also resulted in altered intracellular pH changes
and tumor cell death [8]. Our in vitro studies and those of others
[13–16] have shown that inhibition of lactate transport in tumors with
α-cyano-4-hydroxycinnamic acid (abbreviated as ACCA, α-CCA,
4CIN, or as CHCA; MW = 189.2), a small-molecule competitive in-
hibitor of mammalian lactate transporters [17], can cause growth in-
hibition of tumors or tumor cell death. Furthermore, we [13] and
others [18,19] have shown that application of ACCA will impact tu-
mor metabolism to enhance its radiosensitivity by up to 10-fold.
We hypothesized that disruption of lactate efflux through applica-
tion of ACCA directly to the tumor mass (in vivo) or to the tumor
microenvironment should either halt or significantly inhibit the tu-
mor’s growth and capacity to invade the surrounding normal brain
tissues. We hoped that targeting glycolysis will impact the overall en-
ergy balance of the tumor that is crucial for tumor survival, and in
turn, adversely affect the tumor to eventually cause tumor necrosis.
However, we were concerned that such an approach in vivo may also
negatively impact normal brain function because of the interference
with lactate shuttling that occurs between neurons and surrounding
astrocytes during neuronal “firing,” a recently recognized metabolic
phenomenon in normal brain [20,21].
To clarify these issues and to evaluate the utility of small-molecule
inhibitors of MCTs as therapeutic tools for metabolic targeting of
brain tumors, we first investigated the affect of inhibiting lactate ef-
flux in glioblastoma on their invasiveness through Matrigel-based
in vitro invasion assays [22,23] and then with organotypic brain slice
culture assays [24,25]. On the basis of the distinct inhibition of in-
vasiveness observed on the presence of ACCA in the growth medium,
we conducted in vivo studies in an orthotopic brain tumor nude rat
model (Crl: NIH-rnu) using convection-enhanced delivery (CED) of
ACCA to the tumor bed. The results indicated marked inhibition of
tumor growth in vivo, including complete necrosis of tumor tissue in
most of the experimental animals, with no recurrence of tumor once
the chemical was exhausted. We also analyzed select metabolic profiles
of normal brains of control animals subjected to the same therapeutic
dosages of ACCA to test for toxicity or adverse metabolic effects. Anal-
ysis of ACCA concentration gradients across brain of the nude rat
model indicated that pharmacologically relevant ACCA concentrations
were sufficient to cause complete necrosis of the tumor.
Materials and Methods
Cell Lines, Reagents, and Culture Media
Human glioblastoma cell lines U87-MG and U251-MG were ob-
tained from the American Type Culture Collection (Manassas, VA)
and maintained in Dulbecco modified Eagle medium/F-12 medium
(DMEM/F12) supplemented with 10% fetal bovine serum and
the antibiotic gentamicin. Media and reagents were purchased from
Invitrogen (Carlsbad, CA). Fetal bovine serum was obtained from
Atlanta Biologicals (Atlanta, GA). Basal DMEM (glucose-, glutamine-,
phenol red–, and glutamine-free) was obtained from Mediatech, Inc
(Manassas, VA).
Enhanced Green Fluorescent Protein Expressing Glioma Cells
The two glioma cell lines were engineered to express enhanced
green fluorescent protein (EGFP) for use in the invasion assays de-
scribed herein. In brief, EGFP complementary DNA was amplified
with polymerase chain reaction from the plasmid EGFP-N1 (Clontech,
CA) and cloned into the EcoRI and XhoI restriction sites of a bicis-
tronic retroviral expression vector pLXRN [26]. Recombinant retro-
virions were generated through the PA317 amphotropic packaging
cell line using established protocols [27,28]. Glioma cells were trans-
duced with the retrovirions at a multiplicity of infection of 10 in the
presence of 8 μg/ml polybrene and passaged in the presence of ge-
neticin (G-418; 0.75 mg/ml) until 100% of the cells expressed EGFP
as observed by fluorescence microscopy (fluorescein isothiocyanate
filter; excitation, 480 nm; emission, 535 nm).
Reagent Preparations
Stock solutions of 0.1 M α-cyano-4-hydroxycinnamic acid (ACCA)
were prepared in basal DMEM and the pH was adjusted to 7.4 with
NaOH. Stock solutions of pyruvate, lactate, or glucose (50 mM) were
also prepared in basal DMEM (pH 7.4). All solutions were filter steril-
ized using 0.22-μm syringe-filter units (Millex-GV, Molheim, France).
Oxygen Consumption Assay
U87-MG glioma cells maintained in complete DMEM/F12 me-
dium were detached with Accutase (an invertebrate-derived cell de-
tachment solution; Innovative Cell Technologies, San Diego, CA),
washed once in complete DMEM/F12 medium, and were resus-
pended at 0.5 × 105 cells/μl in the same medium. An oxygen electrode
(Mitocell 200A; Strathkelvin Instruments, Glasgow, UK) equipped
with a fast-response fluorinated ethylene propylene membrane was
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used to measure O2 consumption at 25°C. In brief, the electrode was
calibrated with air-saturated water (high-point, 267 μM) and 2% (wt/
vol) Na2SO3 in 0.01 M Na3BO3 buffer (zero point). Respiration rates
were measured in 10-minute intervals first with 0.5 × 106 cells resus-
pended in 200 μl of DMEM/F12 medium, followed by addition of
10 mM ACCA (20 μl of 0.1 M ACCA). Then, 5 μl of 1.6 mM digi-
tonin was added to permeabilize the cell membranes. The ACCA and
digitonin concentrations used were as described by us previously [13].
Matrigel-Based Invasion Assay
Twenty-four-well tissue culture plates (Falcon; BD Biosciences,
Bedford, MA) and fluorescence blocking well inserts (Falcon HTS
FluoroBlok Inserts; pore size, 8 μm; growth area, 0.3 cm2) were used
for the assays. Matrigel (8 mg/ml; BD Biosciences) was diluted 1:3 in
basal DMEM supplemented with 2 mM glutamine. Twenty-microliter
aliquots of Matrigel suspension were applied to the FluoroBlok well
inserts placed in each well and allowed to set at 37°C. The inserts were
then placed in the 24-well plates containing 0.75 ml of conditioned me-
dium per well (medium from either subconfluent U87-MG or U251-
MG cultures was used as the chemoattractant in the lower chambers).
For the experiments, well inserts were supplemented with 0.5 ml of
1 mM pyruvate, 5 mM lactate, or 25 mM glucose medium that con-
tained EGFP-expressing glioma cells (4 × 104 cells). The pyruvate and
lactate levels were chosen to represent levels that are also physiologi-
cally relevant. Glucose was used at five times the physiological levels
to maintain a high-glycolytic flux across tumor cells. To test for invasion
capacity of glioma on inhibition of MCTs, one set of samples contained
25mMglucose in the well insert, whereas the spentmedium in the lower
chamber was supplemented with 10 mM ACCA. The pH of the sam-
ples was maintained at 7.4. Appearance of cells on bottom surface of
well inserts was monitored through fluorescence microscopy. After
48 hours, fluorescence of the top and bottom surfaces of the inserts
was quantified using a fluorescent plate reader (Tecan-Ultra, Durham,
NC), and the invasive capacity was calculated (fluorescence on bottom
surface of insert/total fluorescence from both surfaces of insert).
Organotypic (Brain) Slice Culture Invasion Assay
All animal experiments were done according to institutionally ap-
proved animal protocol guidelines.Nude rats, weighing 450-500 g, were
anesthetized intraperitoneally with a mixture of ketamine (90 mg/kg)
and xylazine (10 mg/kg), and the skull was exposed under sterile con-
ditions. The spinal column was severed with a sharp scalpel, and a
midsagittal cut was made along the skull to expose the brain. The brains
were rapidly extracted, washed in cold (4°C) basal DMEM and placed
in a 0.5-mm coronal rat brain matrix (Braintree Scientific, Braintree,
MA) bathed in basal DMEM. Brain slices were obtained using tissue
slicer blades (Thomas Scientific, Swedesboro, NJ) and separated into
sterile dishes. Tissue disks, 8 mm in diameter, were obtained from the
slices using disposable dermal biopsy punches (Miltex, York, PA) and
expirated into FluoroBlok well inserts filled with basal DMEM. The
medium was then carefully aspirated to settle the brain slices on to
the insert’s membrane. Any irregular gaps between the brain slice and
thewall of thewell insert were sealed with 5 to 10 μl ofMatrigel prepared
as described and allowed to set. EGFP-expressing glioma cells (4 ×
104 cells) were placed on top of the brain slices in 50 μl of basal DMEM
as a cushion and allowed to incubate for 30 minutes. Well inserts were
then supplemented with 0.5 ml of 1 mM pyruvate, 5 mM lactate, or
25 mM glucose. Conditioned medium (0.75 ml per well, from glioma
cultured DMEM containing 10% fetal bovine serum) was used as a
chemoattractant in the lower chambers. To test for invasion capacity
of glioma when lactate transport is inhibited, a set of samples contained
25 mM glucose in the well insert, whereas the spent medium in the
lower chamber was supplementedwith 10mMACCA. After 120 hours,
fluorescence of the top and bottom surfaces of the inserts was quanti-
fied using a fluorescent plate reader (Tecan-Ultra), and the invasive
capacity was calculated (fluorescence on bottom surface of insert/total
fluorescence from both surfaces of insert). Aliquots of brain slices main-
tained in separate wells were withdrawn from culture every 24 hours,
and their viability was tested using trypan blue exclusion assays. For
this, brain slice fragments were dispersed with Accutase at room temper-
ature, and the suspensions were tested for viability. The brain slices
maintained a minimum of 95% viability throughout the duration of
the invasion assay experiments.
To quantify fluorescence on top surface of well inserts, the spent
medium was aspirated and the wells were gently rinsed with 0.5 ml
of phosphate-buffered saline (PBS). A 4500-μm well border was as-
signed in the plate reader software to read the well insert surface only,
in a 9 × 9 filled circle matrix. Excitation and emission wavelengths
used were 485 and 520 nm, respectively (preset manual gain of
100). The plates were read without lids to prevent background light
scattering. Sham well inserts with either Matrigel or brain slices were
used to compensate for background fluorescence. To read the bottom
surface, the inserts were briefly dipped in 0.5 ml of PBS, the plastic
placeholder flanges were snipped off, and the inserts were placed in-
verted in a fresh 24-well plate. The bottom surfaces were read using
the same parameters as for the top surfaces. The above procedures were
followed to minimize fluorescence quenching and background effects
by both the culture medium and the ACCA.
Intracranial Implantation of U87-MG Glioma in a
Nude Rat Model
An orthotpic xenograft nude rat model (Crl: NIH-rnu; Charles River
Laboratories, Wilmington, MA) was used in this study. In brief, 8- to
10-week-old (250-300 g) male rats were anesthetized as before and im-
mobilized on a rodent stereotaxic device (Kopf Instruments, Tujunga,
CA). The surgical zone was prepared with povidone-iodine according
to approved animal protocols, a 1-cm incision was made retro-orbitally
along the sagittal plane, and the skull was exposed. A burr hole (with-
out penetrating the dura) was created 2 mm lateral to the bregma and
1 mm anterior to the coronal suture [29]. U87-MG glioma cells (1 ×
106 cells suspended in 10 μl of PBS supplemented with 25 mM glu-
cose) were inoculated into the caudate-putamen (CPu) region. The
glioma cells were slowly injected at a depth of 5 mm from the skull
using a Hamilton syringe (10 μl, Model 80301) fitted with a 27-gauge
needle (tapered end directed toward midline), positioned with a syringe
attachment fitted to the stereotaxic device. After 5 minutes, the needle
was slowly withdrawn, and the skin incision was first sutured closed and
then approximated with Dermabond (Closure Medical Corporation,
Raleigh, NC).
Programmed Orthotopic Delivery of ACCA to the Tumor Bed
Fourteen days after tumor implantation, the animals were imaged
by magnetic resonance imaging (MRI) to visualize the bulk tumor.
The animals were anesthetized under sterile conditions as described
previously, and the previous surgical site was reexposed. A nonmetal-
lic (MRI-compatible) brain infusion cannula made of silica (5 mm in
length, 0.36 mm in diameter; catalog no. 328OP/FS; Plastics One,
Roanoke, VA) was connected through a 3-cm-long polyethylene tube
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to an osmotic pump (200-μl capacity, with a 28-day delivery period
[catalog no. 2004; 0.25 μl/h]; Alzet, Cupertino, CA). The pumps were
primed with saline (control animals) or with either 20 or 40 mM
ACCA in PBS buffered to pH 7.4 (test animals). The cannula was
lowered through the previous burr hole to the same depth as for the
tumor inoculation to “hit” the tumor core. The cannula was then sealed
to the skull with cyanoacrylate adhesive (Loctite 454; Loctite Corp,
Rocky Hill, CT). The osmotic pump was inserted into a subcutaneous
cavity created in the midscapular region. Afterward, the entire surgical
area was flushed with saline before suturing of the skin incision, fol-
lowed by application of Dermabond to seal the scalp.
Magnetic Resonance Imaging
MRI of the tumor-implanted nude rats was carried out at theMRRe-
search Facility, Wayne State University in a Bruker Biospec AVANCE
small-animal imager (Bruker Instruments, Billerica, MA) equipped with
a 4.7-T horizontal bore magnet. Brain images were acquired using T1-
and T2-weighted scans. MRI was performed to confirm intracranial
tumor growth 1) before orthotopic placement of cannulae coupled to
either saline- or ACCA-primed osmotic pumps (described above) and
2) subsequently, to monitor tumor growth or regression. Before imag-
ing, each animal was anesthetized by intraperitoneal injection of keta-
mine and xylazine (as described under surgical procedures) to prevent
animal movement within the magnet during imaging. 0.3 mmol/kg of
gadopentate dimeglumine (Magnevist, Berlex Laboratories, Montville,
NJ) was applied through tail vein catheterization for contrast enhance-
ment. A receive-only surface coil (30 mm in diameter) was placed over
the skull area, and the animal was placed in the magnetic coil (72 mm in
diameter) for the procedure. Two-dimensional multislice T2-weighted
and T1-weighted fast-spin echo sequences were used to acquire coronal
and sagittal images of each animal. Each imaging run was completed
within 5 minutes. The initial image was obtained 14 days after implan-
tation of tumor to verify tumor growth. The second image was obtained
after cannulation of the tumor. The surviving animals were imaged
again at 28 days (14 days after osmotic pump application) and then
again at 56 and 120 days.
Experimental End Points
Both control (saline) and test (ACCA) animals were provided food
and water ad libitum, and maintained under sterile conditions. Tumor
shrinkage or growth was monitored by MRI as described above. Ani-
mals were removed from the experiment 1) at 120 days after tumor
implantation or 2) because of pain or trauma (due to excessive tumor
growth). The animals were imaged again at experimental end points
and killed by CO2 narcosis followed by bilateral pneumothorax. Af-
ter sacrifice, brains were rapidly recovered by making a sagittal excision
along the dorsal surface of the skull, and placed in formalin (4% vol/
vol) buffered with PBS. The fixed tissues were paraffin-embedded and
sectioned in 2-μm coronal slices both anterior and posterior to the
cannula implantation site, and the slices were processed for histology
(hematoxylin and eosin [H&E] staining).
Analysis of ACCA Diffusion during CED in the
Orthotopic Nude Rat Model
The same stereotaxic coordinates as described above for tumor im-
plantation were used in this procedure using 28-day Alzet osmotic
pumps primed with saline or 40mMACCA in PBS (pH 7.0). The can-
nulae were implanted into the CPu region in 300- to 350-g nude rats
(n = 4 per group). The animals were provided food and water ad libitum
and monitored for 2 weeks for any weight loss or adverse neurologic
symptoms (including gait, grooming, and response to handling). At the
end of 2 weeks, the animals were killed by CO2 narcosis, and brains were
removed intact. Brains were immediately placed in a 0.5-mm coronal
brain matrix (Braintree Scientific), and 1.0-mm-thick coronal slices were
excised anterior to—and posterior to—the cannulation site. These were
then weighed and stored at −80°C until processed for high-performance
liquid chromatography–mass spectrometry (HPLC-MS) analysis (de-
scribed below) to quantify ACCA concentrations in each slice.
The extraction and analysis of ACCA were carried out at the on-site
pharmacology core facility at Karmanos Cancer Institute. Immediately
before analysis, each slice was thawed in a water bath at ambient
temperature and homogenized in 1.0 ml of 10 mM ammonium for-
mate (pH 7.5) using a micropestle device (Fisher Scientific, Hanover
Park, IL). The homogenates were extracted in ethyl acetate and re-
solved by HPLC (Xterra MS C18 3.5-μm column, 2.1 × 50 mm) with
70% methanol/ 10 mM ammonium formate, pH 7.5, as the elution
buffer on a separation system (Model 2695; Waters, Milford, MA).
Prepared standards of ACCA in same buffer were used to calculate
the concentration of ACCA in the brain slices with Zileuton (N -(1-
benzobthien-2-ylethyl)-N -hydroxyurea)) (Rhodia Pharma Solutions
Ltd, Cramlington, UK) as the internal standard [30]. Drug-free (blank)
rat plasma was obtained from Innovative Research, Dearborn, Mich.
ACCA in the eluates were detected using aWaters QuattroMicro triple
quadrupole mass spectrometric detector equipped with an electro-
spray ionization source.
1H Magnetic Resonance Spectroscopic Analysis of Metabolic
Changes in Brain on CED of ACCA
To ascertain possible metabolic changes in the brain of the experi-
mental animals, we delivered saline or 40 mM ACCA through CED
to the same stereotaxic coordinates as before using 200- to 250-g nude
male rats (n = 2 per group). Two weeks after ACCA application, ani-
mals were decapitated, brains were rapidly removed onto a chilled
brain matrix, and 2-mm-thick coronal slices were obtained. The slices
were frozen on solid CO2, and 1.5-mm-diameter punches were ob-
tained from individual slices from the left hemisphere (where cannulae
were placed). The punches were obtained from regions immediately
below the cannula opening, that is, centered approximately 2 mm
from the midline with the dorsal border tangential to the cortical-
hippocampal fissure and contained elements of CA1, CA2, and CA3
as well as the dentate gyrus [31]. Frozen punches were transferred to
microcentrifuge tubes and stored at −80°C until high-resolution magic
angle spinning (HR-MAS) 1Hmagnetic resonance spectroscopy (MRS).
Frozen intact tissue samples were weighed (∼2 mg) and placed di-
rectly into a Bruker zirconium rotor (4 mm in diameter, 10 μl in capac-
ity) containing 5 μl of buffer (100 mM potassium phosphate, pH 7.4,
200 mM sodium formate, 1 g/L NaN3, and 3 mM trimethylsilyl-
propionate) diluted with an equal volume of D2O containing 0.75%
3-(trimethylsilyl)-propionic acid (TSP). TSP serves as an internal chem-
ical shift reference (0.00 ppm), formate (8.44 ppm) is used for phase
corrections, whereas D2O is used to lock on the center frequency. The
rotor (with sample) was placed into a Bruker magic angle spinning
probe maintained at 4°C in a vertical wide-bore (8.9 cm) Bruker
11.7-T magnet with an AVANCE DRX-500 spectrometer (Bruker
Biospin Corp, Billerica, MA). Rotors were spun at 4200 ± 2 Hz at
54.7 degrees relative to the static magnetic field B0. Compensation of
field inhomogeneities, pulse sequences, and signal acquisitions was car-
ried out as described previously by us [32].
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In brief, signals were acquired with Bruker XWINNMR (v 3.6 soft-
ware) and the identical brain regions from all animals in an experimen-
tal cohort were analyzed in the same session. Spectra were analyzed
with a custom LC Model software package (ver. 6.1-4) using a linear
combination of 27 individual neurochemical model spectra (basis set)
as well as nonspecific lipid signals to fit the tissue spectrum and calcu-
late absolute concentration values for neurochemicals with signals be-
tween 1.0 and 4.2 ppm [33].
The precision of the LC Model fit to the spectral data was estimated
with Cramér-Rao bounds; CRB were typically less than 10% and me-
tabolites with CRB greater than 25% were not considered for further
analysis. To account for variations in the mass of individual samples,
absolute concentrations of MR-visible metabolites were corrected for
tissue weight and expressed as nanomoles per milligram of wet tissue
weight; variance associated with means suggests a substantial degree of
analytical reproducibility [32].
Statistical Analysis
Statistical analyses were carried out using SigmaPlot 9 program
(Systat Software, San Jose, CA). Unless otherwise indicated, re-
sults are reported as mean ± SD. Survival was estimated using the
Kaplan-Meier analytical method [34]. P values were calculated using
Figure 1. ACCA inhibits glucose mediated glioma invasiveness across Matrigel and organotypic brain slice cultures. Migration of EGFP-
expressing glioma cells across Matrigel-coated transwell inserts or across 0.5-mm-thick coronal slices from the CPu region of immu-
nodeficient rat brains were evaluated. Invasion across Matrigel of U87-MG (A) and U251-MG (C) (n = 4 per metabolite) or across coronal
brain slices of U87-MG (B) and U251-MG (D) (n = 4 per metabolite) were plotted as fold invasion. Fold invasion = fluorescence of
[(transwell bottom read) / (transwell top + bottom reads)]. Data shown as mean ± SEM. P values are indicated in comparison to glucose
data. ***P < .01, **.01 < P < .05, *.05 < P < .1. Unmarked data sets had .1 < P < .5.
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Student’s t test or the Mann-Whitney rank sum test and considered
statistically significant when P < .05. One-way analysis of variance
with pairwise multiple comparisons (Holm-Sidak) was carried out
for data analysis of invasion assays.
Results
Glycolytic Flux Directly Modulates Glioblastoma Invasion
Matrigel-based invasion assays have been the standard method to
evaluate invasive capacity of tumor cells in vitro. We investigated the
ability of glioma cells to invade across Matrigel under alternate met-
abolic stimuli and also analyzed the “invasiveness” of glioma cells in a
setting more relevant in an in vivo environment using organotypic
brain slice culture–based invasion assays. Comparison of the invasive
capability of U87-MG and U251-MG glioma cells across both
Matrigel and brain slice cultures indicated that 25 mM glucose
enhanced invasive capacity over both pyruvate (1 mM) and lactate
(5 mM) (Figure 1). Thus, enhancing glycolytic flux with glucose
correlated with the ability of glioma cells to invade. However, sup-
plementation of medium with lactate did not significantly stimulate
invasive capacity, with invasive rates being mostly slightly higher
than that for pyruvate. Despite this, when glucose-stimulated gli-
oma cells were challenged with ACCA (to inhibit lactate efflux and
collapse the glycolytic metabolism), we saw a significant two- to
three-fold drop in the invasive capacity of the glioma cells, with
the magnitude dropping to basal levels.
It should be noted that we chose 10 mM ACCA as the challenge
concentration in the above experiments, as our previous in vitro studies
[13] had indicated that, whereas 10 mM ACCA is inhibitory to lactate
efflux, it does not result in apoptosis or necrosis of the glioma cells.
Extracellular Application of ACCA Does Not Impart Adverse
Effects on Mitochondrial Respiration
Previous studies by us using spectrophotometry have indicated that
ACCA remains extracellular (thus does not directly impact mitochon-
drial pyruvate transport) unless the cell membranes are permeabilized
(e.g., with digitonin) [13]. However, because of previous reports on
impact of extracellular ACCA on mitochondrial respiration in intact
tissue preparations [35], measurements were carried out to determine
potential impact on mitochondrial respiration on in vivo application
of ACCA. The results confirmed our prior spectrometric data and
indicated that ACCA impacts mitochondrial respiration only on per-
meabilization of cells (Figure 2A). The respiratory rate remained un-
changed on addition of ACCA, but subsequent addition of digitonin
resulted in a brief respiratory burst most likely because of permeabili-
zation of cells and exposure of mitochondria to respiratory substrates,
followed by inhibition of respiration as ACCA blocked mitochondrial
pyruvate entry (Figure 2B).
Convection-Enhanced Delivery of ACCA to the Tumor Bed
Causes Necrosis of U87-MG Glioma
Previous in vitro studies by us have indicated that 20 mM ACCA
was sufficient to induce both apoptotic and necrotic cell death in
U87-MG glioma cells, with approximately 70% cells becoming ne-
crotic, whereas 10% cells remained apoptotic [13,36]. To test the
in vivo efficacy of ACCA in killing glioma, we chose an orthotopic
brain tumor nude rat model, in which ACCA was applied directly to
the tumor bed. ACCA was continuously administered through CED
[37–39] during a 28-day period to the center of the tumor using mini-
osmotic pumps (Alzet). In the first set of experiments, two alternate
ACCA concentrations, namely, 20 and 40 mM, were tested first.
When administered at 20 mM, the animals (n = 3) survived a mean
of 48% longer than control animals that received saline in their os-
motic pumps. Studies with 40 mM ACCA treated animals (n = 3)
survived the longest (224%; n = 2), with the third animal indicating
complete remission (necrosis) of the tumor (by MR imaging) and then
surviving beyond the experimental end points even after the ACCA
was exhausted in the osmotic pumps (Figure 3A).
Thereafter, we completed a second set of experiments with six ani-
mals per group using 40 mM ACCA only (Figure 3B). Of the test
animals, three survived 212% longer than control animals that were
treated with saline. MRI of the other three test animals indicated
complete necrosis of tumor, and all three animals survived beyond
the experimental end points (3 months after tumor implantation)
with no recurrence of the tumor after ACCA was exhausted in the
osmotic pumps (Figure 4, A–D). Thus, in this cohort, a 50% tumor-
free survival rate was observed.
Figure 2. Extracellular ACCA does not inhibit O2 consumption rate
of U87-MG glioma cells. (A) Upper trace: Cells (0.5 × 106) were
added to DMEM/F12 medium maintained at room temperature (ar-
row 1) and rates of O2 consumption traced for 10 minutes; ACCA
was added to 10 mM final (arrow 2) and respiration measured for
another 10 minutes, followed by addition of digitonin (40 μM final).
Lower trace: O2 consumption of cells incubated for a similar du-
ration but in the absence of ACCA or digitonin. Lines A, B, and C
mark the time intervals that were used to plot O2 consumption
rates (n = 3) at each step (B).
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Orthotopic Application of ACCA to Brains of
Non–Tumor-Bearing Nude Rats through CED—While
the Animals Displayed Normal Weight Gains and
Lack of Tissue Necrosis at the Application Site, Altered
Metabolic Profiles Were Observed in Adjacent Tissue
One of our main concerns was that CED delivery of ACCA at mM
concentrations may adversely impact the neuron-astrocyte lactate shut-
tle that is now recognized as crucial for normal neuronal function and
metabolism [20,21]. To test, we cannulated the CPu region of non–
tumor-bearing nude rats (n = 6 per group) in the same stereotaxic co-
ordinates as those used for tumor implantation and applied either
phosphate-buffered saline (Dulbecco PBS) or 40 mM ACCA through
osmotic pumps at the same delivery rates as described previously. Ani-
mals were monitored daily up to 2 weeks after pump implantation to
check for any observable neurologic deficits such as lack of grooming,
mobility, gait, and gain or loss in body weight. Both control (Dulbecco
PBS) and test (ACCA) animals showed normal behavioral patterns
and their body weight gain/loss changes during the 2-week period
did not deviate in a statistically significant manner (P = .277, Mann-
Whitney rank sum test; n = 3 per group) (Figure 5), indicating lack of
apparent toxicity on delivery of 40 mM ACCA to the brain through
CED. At a superficial level, toxicity is not apparent when changes in
body weight are compared with those of tumor-bearing rats (n = 2)
where a continuous loss of body weight by 10% is initially indicated,
until the animals begin responding to ACCA treatment (P ≤ .001,
Mann-Whitney rank sum test) (Figure 5). Furthermore, histologic
(H&E) staining of coronal sections of the 40 mM ACCA-treated con-
trol animals did not indicate any tissue necrosis at the cannulation site
Figure 3. Kaplan-Meier survival analysis of immunodeficient rat
orthotopic glioblastoma models treated with ACCA. (A) Animals
implanted with glioma in the CPu region were subjected to CED
with saline (control animals; n = 3) or ACCA at the indicated
concentrations (test animals; n = 3 per group) and the survival
followed up to 120 days. Day 1 = day of tumor implantation. (B)
A second cohort of animals that were not implanted with tumor
(control; n = 3) were administered 40 mM ACCA in the CPu region
through CED to test for toxicity to ACCA. Two additional groups
were implanted with glioma in the CPu region (n = 6 per group)
at day 1 and treated with saline (0 mM ACCA) or 40 mM ACCA
through CED 14 days after tumor implantation, and survival was
monitored up to 120 days after tumor implantation.
Figure 4. Coronal MR scans of immunodeficient rat orthotopic
glioblastoma models treated with ACCA. Representative coronal
MR scans of one of the six animals that survived beyond experi-
mental end points is shown. Gadolinium contrast–enhanced im-
ages are shown at the cannulation point. (A) Day 1, immediately
after implantation of tumor in the CPu region; the needle tract is in-
dicated by arrow. (B–D) Images of the same coronal position at
day 14 (day of osmotic pump implantation and cannulation of the
tumor for CED of ACCA), day 56 (42 days after CED of ACCA and
14 days after exhaustion of ACCA in the osmotic pumps), and
day 120 (106 days after CED of ACCA and 78 days after exhaus-
tion of ACCA in the osmotic pump). Representative images of an
animal that survived to day 120 are shown. (E) Tumor growth at
day 20 in a representative animal that did not receive saline or ACCA
through CED.
626 Metabolic Targeting of Glioma Lactate Efflux Colen et al. Neoplasia Vol. 13, No. 7, 2011
(Figure 6). Histologic analysis of brains of tumor-implanted animals
that survived beyond the experimental end points also indicated that,
whereas complete necrosis of the tumor was observed, there was no
visible damage to the surrounding normal brain tissues (Figure 7).
For example, distinct signs of cellular necrosis including nuclear
pyknosis or amorphous cytoplasmic staining (including cytolysis) [40]
were not visible in the H&E micrographs. These results were also
indicative of uniform and rapid dissemination of ACCA through
CED, from the point of application into the tumor and then across
the brain.
1H MRS was carried out to further evaluate possible metabolic
effects on the normal brain, where tissue punches from saline- or
ACCA-treated animals (n = 2) were obtained (three punches per cor-
onal slice, three slices per animal) immediately adjacent to the can-
nula opening. Of the 27 neurochemical basis set that was analyzed,
10 that had changes in concentration are listed in Table 1. Specific
metabolic intermediates of the tricarboxylic acid cycle indicated
altered metabolic profiles, including those derived from glutamate
or aspartate. Glutamine, γ-aminobutyric acid, and succinate (derived
from glutamate or downstream from glutamate in the tricarboxylic
acid cycle) and N -acetyl aspartate and N -acetyl aspartylglutamate
(derived from aspartate through oxaloacetate) showed statistically sig-
nificant changes in their concentration profiles (P < .05). Lactate
levels, which should be affected because of inhibition of plasma
membrane MCTs by ACCA, also showed a reduction but at a lesser
magnitude (.05 < P < .1).
Figure 5. Percentage weight gain or loss in immunodeficient rats
treated with 40 mM ACCA to the CPu region through CED. Non–
tumor-bearing animals (weight, 300-350 g) were cannulated in the
CPu region at the same stereotaxic location as for tumor implan-
tation (day 0). Saline (n= 3) or 40 mM ACCA (n= 3) were delivered
through osmotic pumps (28-day duration pumps; 200-μl capacity)
for a period of 14 days, and the animals were weighed daily. The
weight gain or loss of tumor-bearing animals that were treated
with 40 mM ACCA through CED are shown for comparison (n =
2; day 0 = day of administration of 40 mM ACCA through CED,
14 days after tumor implantation).
Figure 6. Histologic analysis of coronal sections of brains of immunodeficient rats treated with 40 mM ACCA through CED. (A) Rep-
resentative H&E-stained coronal section (×10) of one of the animal brains that was evaluated for tissue necrosis at the cannulation
point (cortical region; arrow) after CED of ACCA for 2 weeks. (B) Cannulation point (arrow) at ×40 magnification. (C) Cannulation point
at ×200 magnification.
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Orthotopic CED of ACCA to the Brains of the Nude Rat
Model Results in ACCA Concentration Gradients That Are
Pharmacologically Relevant
Next, we evaluated the in situ ACCA concentration gradients in
the rat brains after a 2-week period of drug application through
CED, using the same conditions as described in the previous para-
graph. Coronal sections, 1.0 mm in thickness, were excised of the
freshly isolated rat brains using a 0.5-mm brain matrix as described
under Materials and Methods. ACCA concentrations in the clarified
tissue homogenates were evaluated through HPLC-MS taking into
account a mean brain tissue density of 1.04 [41]. The analyses indi-
cated a maximum concentration of approximately 40 μM ACCA in
the coronal sections (slice P1; Figure 8A) immediately posterior to
the cannulated position (slice 0; Figure 8A), with concentration gra-
dients dropping to 3 μM or less at distances of 5 to 6 mm from the
point of application. Furthermore, levels of ACCA in the plasma
from the above animals were below detection limits of the HPLC-
MS when signal-to-noise ratios were normalized against control plasma
from rats that were not exposed to ACCA.
Discussion
Glioblastomas are the most malignant of brain tumors and, in com-
mon with most other highly malignant tumors, harbor aberrant met-
abolic pathways. Most recognized is their propensity to maintain an
elevated glucose to lactic acid flux, necessitating the tumor to efflux
lactic acid to the microenvironment. Thus, disruption of this last step
(by inhibiting the MCTs that facilitate efflux) presents a “choke-
point” that can be harnessed to destroy the glioblastoma preferably
without affecting the surrounding normal brain tissue.
In this study, we used established glioblastoma cell lines to show
that inhibition of lactate efflux in glioblastoma with α-cyano-4-hydroxy
cinnamic acid (ACCA) will adversely impact both invasive and prolif-
erative capacities of the tumor. Most significantly, we also show that
ACCA, when applied directly to the tumor bed in an orthotopic brain
tumor model through CED, can bring about complete tumor necrosis
Figure 7. Histologic analysis of coronal sections of brains of tumor bearing rats after treatment with 40 mM ACCA through CED. (A) Rep-
resentative H&E-stained coronal section (×10) of brain of one of the animals that survived beyond experimental end points. Cannulation/
posttumor necrotic tissue cavity (striatal region; arrow) 120 days after CED of ACCA. (B) Necrotic cavity (arrow) at ×40 magnification.
(C) Cavity wall at ×200 magnification.
Table 1. Alterations in Metabolic Profile of Normal Brain in Response to CED of ACCA to
the Striatum.
Metabolites Application
Saline ACCA (40 mM)
Creatine 4.67 ± 0.24 4.00 ± 0.38
γ-amino butyric acid 2.22 ± 0.17 1.54 ± 0.08*
Glutamine 2.43 ± 0.13 1.62 ± 0.17*
Glutamate 7.57 ± 0.48 5.68 ± 0.61*
Glycerophosphoryl-choline 0.85 ± 0.05 0.77 ± 0.09
myo-inositol 3.85 ± 0.23 3.47 ± 0.31
Lactate 7.46 ± 0.50 5.79 ± 0.73†
N -acetyl aspartate 4.37 ± 0.30 3.24 ± 0.33*
N -acetyl aspartylglutamate 1.11 ± 0.07 0.82 ± 0.05*
Succinate 0.36 ± 0.03 0.23 ± 0.01*
Metabolite concentrations are shown in nanomoles per milligram of wet tissue weight. Values are
given as mean ± SEM.
*Statistically significant changes (P < .05) in metabolite concentrations.
†Changes with .05 < P < .1.
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without causing damage to the surrounding normal brain tissues. A
50% survival rate was observed with the nude rat model with no tumor
recurrence after treatment. Furthermore, we have determined the phar-
macologically relevant ACCA concentration gradients that are estab-
lished in the model to impart tumor necrosis.
Of the four known functional MCTs (MCTs 1-4) that transport
lactate, all, except MCT3, are currently known to be overexpressed
in tumors [8,42,43]. All four isoforms are expressed in normal brain
with MCT1 and MCT4 predominating in astrocytes, whereas MCT2
is preferentially expressed in neurons [44,45]. MCT3 is located pri-
marily in the choroid plexus and the retinal pigment epithelium
[46]. Thus, a small-molecular inhibitor approach, as described in
our studies, need to show partiality toward targeting the tumor while
having minimal impact on the surrounding brain tissue, particularly
on the astrocyte-neuron lactate shuttle that occurs between neurons
and astrocytes during routine axonal firing [20,21].
We chose ACCA because it harbors a high K i (0.5 mM) against
lactate transporters in tumors [17]. Although it is also known to in-
hibit pyruvate entry in isolated mitochondria [47], our current and
previous in vitro studies have indicated that ACCA remains extracel-
lular and thus should not impart adverse effects on mitochondrial
pyruvate entry in intact cells [13]. Whereas small-molecule inhibitors
of MCTs with higher affinity (K i of approximately 1-10 nM) have
been reported recently [48–50], our primary concern was that such
high-affinity inhibitors may also disrupt the neuron-astrocyte lactate
shuttle. Thus, it was hoped that ACCA, with a higher K i (lower af-
finity toward MCTs), may have relatively low impact on the normal
brain tissue while adversely affecting the highly elevated glycolytic
metabolism of the glioblastoma.
Our previous in vitro studies have indicated that the glycolytic me-
tabolism in these malignant tumors collapses on inhibition of lactate
efflux [13,36]. In this report, our first goal was to identify whether in-
hibition of lactate efflux could adversely affect the glioblastoma’s highly
invasive nature. Our results with both Matrigel-based and brain slice
culture–based invasion assays clearly indicated the inhibitory effects of
ACCA on glioma invasion. The observed inability of 5 mM lactate to
stimulate invasion at a magnitude similar to that with 25 mM glucose
may be due to the use of lactate by the tumor cells toward their me-
tabolism because the glioma cells were presented with only glutamine
(2 mM) and 5 mM lactate as metabolic substrates in these “lactate”
sample sets.
Both invasion assay methods showed similar fold inhibition of
glucose-stimulated invasive capacity of glioblastoma cells by ACCA
(supporting our hypothesis that disruption of lactate efflux by tumors
will adversely affect invasive capacity). Our results may also indicate
the importance of the stroma in modulating the invasiveness, a point
expounded by other researchers [51]. For example, efflux of lactate by
the tumor cells could directly modulate the stromal microenviron-
ment to promote invasion rather than the mere enhancement of lac-
tate levels around the tumor mass. Whereas it is known that tumor
lactate can modulate extracellular matrix proteins in the tumor micro-
environment [52,53], a recent report on glioma indicates that lactate
can initiate a cascade of events to upregulate both expression and ac-
tivity of transforming growth factor β and matrix metalloproteinase 2
and enhance the invasive capacity of glioma [54].
The above observations also correlate with the proton driven tu-
mor invasion hypothesis proposed by Gatenby et al. [55–57], which
was recently tested in a murine model using a bicarbonate-buffered
system [58]. Thus, not only protons but also lactate are indicated to
promote the invasiveness of tumors into the surrounding normal tis-
sue environment. However, we cannot discount the possibility that
collapse of glycolytic metabolism in the glioma cells (on inhibition of
lactate efflux) may also have resulted in overall energy paucity in the
tumor cells to contribute toward inhibition of invasive capacity.
Our primary concerns in a potential clinical applicability of meta-
bolic targeting of glioma with ACCA or a similar drug were two-fold.
First, from a pharmacological standpoint, ACCA had low potency
(millimolar concentrations of ACCA were needed in vitro to cause ne-
crosis in glioma) [13]. Second, in vivo, ACCA may interfere with the
lactate shuttle between astrocytes and neurons and result in potentially
lethal consequences.
Polar chemotherapeutics that target brain tumors are routinely and
directly administered to the brain parenchyma surrounding the tumor
Figure 8. CED-mediated distribution of ACCA in immunodeficient
rat brains. (A) Coronal brain sections, 1 mm in thickness, were ob-
tained from animals that received 40 mM ACCA for 14 days
through CED to the CPu region (non–tumor-bearing rats). Sections
were weighed and processed for HPLC-MS analysis for ACCA con-
centration per slice. Slice 0 indicates cannulation point; slices A1–
A3, anterior slices at 1-mm intervals from the cannulation point;
slices P1–P3, posterior slices at 1-mm intervals from the cannula-
tion point. (B) The ACCA concentrations (micrograms per gram of
wet weight of brain) recorded were 0.195 ± 0.27 (A3), 0.0385 ±
0.54 (A2), 1.16 ± 0.06 (A1), 5.11 ± 0.24 (0), 7.21 ± 1.06 (P1), 2.52 ±
0.01 (P2), 0.595 ± 0.17 (P3).
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resection cavity to circumvent the blood-brain barrier, which effec-
tively limits penetration by these drugs when applied through the sys-
temic route [37]. We also chose direct application of ACCA to the
tumor bed in our animal model because the molecule is anionic at
physiological pH. To enhance diffusion of the drug throughout the
tumor and the surrounding brain parenchyma, we applied the drug
through CED by maintaining a pressure gradient through infusion
with osmotic pumps. Application of ACCA directly to the tumor
bed in our orthotopic nude rat brain tumor model resulted in highly
promising results with a 50% survival rate when challenged with
ACCA. In these surviving animals, the tumor had not recurred after
28 days of drug application (after the pumps “run dry”), and indicated
complete necrosis of the tumor, which was verified by both MRI and
histochemical staining. The surviving animals lived beyond the initially
targeted experimental end points of 30 days after drug application and
with normal weight gains and behavior/mobility.
The absence of adverse neurologic symptoms when naive (control)
animals were challenged with orthotopic delivery of 40 mM ACCA
through CED to the brain was also significant because it indicated
that programmed delivery of low affinity lactate transporter inhibi-
tors (even at millimolar concentrations) did not significantly affect
brain function. Although these animals displayed normal weight
gains and behavior, our 1H MRS analyses indicated that there were
changes in the brain metabolite profiles due to CED of ACCA. Not
surprisingly, the 2-week infusion of ACCA decreased lactate as well
as other mitochondrial constituents such as N -acetyl aspartate, glu-
tamate, and succinate. In the absence of any histologic evidence for
neuronal death, decreases in these metabolic intermediaries suggest
that neurons and glia, in contrast to tumor cells, have shifted to com-
pensatory pathways to maintain energy equipoise.
The thousand-fold lower ACCA concentrations (10-40 μM) de-
tected across the brain parenchyma and the lack of observable necrosis
at cannulation points indicated that distribution of the drug is rapid
through CED. Thus, pharmacologically applicable micromolar levels
of ACCA had been sufficient to cause tumor necrosis in our studies.
However, studies have indicated that serum factors such as albumin
can bind ACCA and thus reduce the availability of the inhibitor at
the tissue level [35]. Thus, the marked reduction in ACCA concen-
trations that was observed may be due to sequestration of ACCA by
serum components. However, when the drug efflux rates by the os-
motic pumps (0.25 μl/h) and the brain volumes (∼2 ml per 400-g
rat) of the experimental models are taken into consideration, a micro-
molar level of drug concentrations are feasible under steady-state con-
ditions. Studies by others have indicated that CED at 1 μl/h can result
in a drug diffusion radius of 0.5 cm from the cannula opening in a rat
brain model [59].
Although ACCA was below detection limits in the systemic circula-
tion, analysis of ACCA concentration across the brains along the sagittal
plane indicated a normal distribution pattern, interestingly with slightly
higher ACCA levels immediately posterior to the cannulation point.
Whether the latter was due to influence of the anterior-to-posterior
bulk CSF flow in the ventricular system needs to be determined.
Two previous studies have targeted the pyruvate–acetyl CoA–lactate
metabolic axis of tumors with small-molecule drugs in rodent models.
Decreased tumor size was reported in one study where dichloroacatate
was provided ad libitum to channel the axis toward mitochondrial
respiration (pyruvate to acetyl CoA) [60], with the studies currently
advancing to clinical trial stage [61]. The other study examined intra-
peritoneal bolus application of ACCA against subcutaneously im-
planted breast tumors to show tumor growth inhibition and necrosis
at the hypoxic tumor core [18]. In contrast, the studies we report here
with the orthotopic brain tumor model show that programmed appli-
cation of ACCA to the tumor bed through CED to the tumor bed will
not only increase overall survival of the treated animals but also cause
complete necrosis of the tumor in half of the treated animals with no
recurrence. To the best of our knowledge, this is the first report on
CED of MCT inhibiting small-molecule drugs to the tumor bed in
a brain tumor (or solid tumor) model to demonstrate tumor necrosis
with no recurrence in a subset of the treated animals. We also show
that, while there is some impact on the profile of metabolic interme-
diaries in brain due to orthotopic delivery of these low-affinity (high-
K i) small-molecule inhibitors of lactate efflux, when administered
through programmed delivery (CED) in an animal model, therapeutic
results can still be achieved against brain tumors without major adverse
neuropathologic effects, which have been a major concern in the tu-
mor metabolism field.
In summary, our ex vivo and in vivo studies implicate the crucial
nature of MCTs and lactate efflux to the survival and dissemination
of tumors. The studies also indicate that intratumoral application of
metabolic inhibitors of glycolysis through CED may be a promis-
ing avenue to target brain tumors in a future clinical setting, perhaps
even before, or in the absence of, surgical debulking. Because malig-
nant gliomas are highly heterogeneous, a therapy as envisaged above,
where lactate efflux is cutoff by using MCT facilitated export as a
“choke-point” will preclude the ability of these tumors cells to bypass
this metabolic insult because alternative pathways do not exist to
compensate and maintain the glycolytic flux, a metabolic facet crit-
ical for the tumor’s survival.
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